fungi News and Research

RSS

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

SPECT/CT with 99mTc-HMPAO-WBC can improve diagnosis of infectious endocarditis

When combined with standard diagnostic tests, functional imaging procedures have been shown to reduce the rate of misdiagnosed cases of infectious endocarditis. According to new research published in the August issue of The Journal of Nuclear Medicine, single photon emission computed tomography (SPECT)/computed tomography (CT) with 99mTc-hexamethylpropleneamine oxime-labeled white blood cells (99mTc-HMPAO-WBC) can improve the diagnosis of infectious endocarditis in hard-to-diagnose cases.

2 Aug 2012

How an opportunistic fungal pathogen knows when to attack

The opportunistic fungal pathogen Candida albicans inconspicuously lives in our bodies until it senses that we are weak, when it quickly adapts to go on the offensive. The fungus, known for causing yeast and other minor infections, also causes a sometimes-fatal infection known as candidemia in immunocompromised patients. An in vivo study, published in mBio, demonstrates how C. albicans can distinguish between a healthy and an unhealthy host and alter its physiology to attack.

25 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Experts examine host recognition of Staphylococcus and E.coli bacteria

We are surrounded by bacteria, viruses, fungi and parasites. The fact that we nevertheless do not fall prey to infections is thanks to certain cellular sensor molecules such as toll-like receptors (TLR), which recognize the molecular structure of pathogens and intercede by ensuring an often completely unnoticeable elimination of the invaders. Their immune-activating abilities were only detected in 1998, a discovery which was awarded with the Nobel Prize

21 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Elevated levels of atmospheric CO2 accelerate soil carbon loss in forests

Elevated levels of atmospheric carbon dioxide accelerate carbon cycling and soil carbon loss in forests, new research led by an Indiana University biologist has found.

11 Jul 2012

Scientists identify novel strategy to target Taspase1 enzyme

Scientists at the University Medical Center of Johannes Gutenberg University Mainz in Germany identified a novel strategy to target the oncologically relevant protein-cleaving enzyme Taspase1.

10 Jul 2012

Raising vitamin D concentrations reduces risk of HAIs among hospital patients

A paper recently published in Dermato-Endocrinology indicates that raising vitamin D concentrations among hospital patients has the potential to greatly reduce the risk of hospital-acquired infections.

4 Jul 2012

Flu immunity depends on number of viruses involved during initial infection

Not only does the type of flu virus affect a patient's outcome, but a new research report appearing in the Journal of Leukocyte Biology suggests that the number of viruses involved in the initial infection may be important too.

29 Jun 2012

MAARA invests £340,000 into vital asthma and allergy research

A charity operating Britain's longest-running pollen database is investing over £340,000 into vital asthma and allergy research at the University of Leicester.

27 Jun 2012

Biological filter to remove estrogens from waste water and drinking water

A biological filter to remove estrogens from waste water and drinking water. The 15 Bielefeld students submitting this project to the 'international Genetically Engineered Machine competition' (iGEM) at the Massachusetts Institute of Technology (MIT) in Boston, USA are setting their sights high.

26 Jun 2012

Emory scientists identify new type of anti-inflammatory compound

Scientists at Emory University School of Medicine have identified a new type of anti-inflammatory compound that may be useful in treating a wide range of conditions, including neurodegenerative and autoimmune diseases. These compounds inhibit the enzyme Nox2, part of a family of enzymes responsible for producing reactive oxygen species (ROS).

22 Jun 2012

Zebrafish provides insight into human melanoma

A transparent member of the minnow family is providing researchers at Weill Cornell Medical College in New York City with insight into human melanoma - a form of skin cancer - that may lead to new or repurposed drug treatments, for skin and other cancers.

19 Jun 2012

Commensal bacteria essential to fight off viral infections

Healthy humans harbor an enormous and diverse group of bacteria and other bugs that live within their intestines. These microbial partners provide beneficial aid in multiple ways - from helping digest food to the development of a healthy immune system.

19 Jun 2012

T2Endotoxin assay extends reach of T2MR detection

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on endotoxin detection at the American Society for Microbiology General Meeting, June 16-19, 2012, in San Francisco, CA.

18 Jun 2012

Caspase-11 enzyme plays an important role in Legionella infection

New research shows that an enzyme that has long been considered relatively useless to the immune response instead has an important role in setting up immune cells to kill infection-causing bacteria.

13 Jun 2012

Aminoacyl-tRNA synthetases important targets for development of new drugs against major diseases

Researchers at the University of Gothenburg, Sweden, are working to develop substances that can prevent parasites, bacteria and fungi from producing essential proteins, research that could, in the long term, lead to new drugs for several major diseases.

12 Jun 2012

Study suggests link between fungi and ulcerative colitis

Cedars-Sinai researchers say their examination of the fungi in the intestines suggests an important link between these microbes and inflammatory diseases such as ulcerative colitis.

7 Jun 2012